somapacitan-beco

somapacitan-beco (SOGROYA) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.

SOGROYA is a marketed brand name for somapacitan-beco. Check FDA Drugs@FDA for the current US label holder and prescribing information.

somapacitan-beco has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.